The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1421
ISSUE1421
July 22, 2013
Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
July 22, 2013 (Issue: 1421)
The FDA has approved crofelemer (kroe fel’ e mer;
Fulyzaq – Salix), a chloride channel inhibitor derived
from the red sap of the South American plant Croton
lechleri, for symptomatic relief of noninfectious
diarrhea in patients with HIV...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.